TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Recruiting

Phase 1

Phase 2

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Sponsor:

Portage Biotech

Code:

NCT04969315

Conditions

Renal Cell Cancer

Castrate Resistant Prostate Cancer

Non Small Cell Lung Cancer

Head and Neck Squamous Cell Carcinoma

Colorectal Cancer (CRC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TT-10

TT-4

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Portage Biotech on 2025-04-02.